WallStSmart

Equifax Inc (EFX)vsSBC Medical Group Holdings Incorporated (SBC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Equifax Inc generates 3609% more annual revenue ($6.28B vs $169.34M). SBC leads profitability with a 24.1% profit margin vs 11.1%. SBC trades at a lower P/E of 7.5x. EFX earns a higher WallStSmart Score of 66/100 (B-).

EFX

Strong Buy

66

out of 100

Grade: B-

Growth: 7.3Profit: 7.0Value: 4.0Quality: 4.5
Piotroski: 5/9Altman Z: 1.89

SBC

Buy

52

out of 100

Grade: C-

Growth: 2.0Profit: 8.5Value: 6.7Quality: 8.5
Piotroski: 2/9Altman Z: 3.94
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EFXSignificantly Overvalued (-21.7%)

Margin of Safety

-21.7%

Fair Value

$162.39

Current Price

$172.13

$9.74 premium

UndervaluedFair: $162.39Overvalued

Intrinsic value data unavailable for SBC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EFX1 strengths · Avg: 8.0/10
EPS GrowthGrowth
34.0%8/10

Earnings expanding 34.0% YoY

SBC6 strengths · Avg: 9.8/10
P/E RatioValuation
7.5x10/10

Attractively priced relative to earnings

Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Operating MarginProfitability
41.1%10/10

Strong operational efficiency at 41.1%

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.9410/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
24.1%9/10

Keeps 24 of every $100 in revenue as profit

Areas to Watch

EFX4 concerns · Avg: 3.8/10
PEG RatioValuation
1.624/10

Expensive relative to growth rate

P/E RatioValuation
28.8x4/10

Moderate valuation

Altman Z-ScoreHealth
1.894/10

Grey zone — moderate risk

Debt/EquityHealth
1.173/10

Elevated debt levels

SBC4 concerns · Avg: 2.5/10
Market CapQuality
$310.60M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Revenue GrowthGrowth
-9.0%2/10

Revenue declined 9.0%

EPS GrowthGrowth
-47.1%2/10

Earnings declined 47.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : EFX

The strongest argument for EFX centers on EPS Growth. Revenue growth of 14.3% demonstrates continued momentum.

Bull Case : SBC

The strongest argument for SBC centers on P/E Ratio, Price/Book, Operating Margin. Profitability is solid with margins at 24.1% and operating margin at 41.1%.

Bear Case : EFX

The primary concerns for EFX are PEG Ratio, P/E Ratio, Altman Z-Score.

Bear Case : SBC

The primary concerns for SBC are Market Cap, Piotroski F-Score, Revenue Growth.

Key Dynamics to Monitor

EFX profiles as a value stock while SBC is a declining play — different risk/reward profiles.

EFX carries more volatility with a beta of 1.31 — expect wider price swings.

EFX is growing revenue faster at 14.3% — sustainability is the question.

EFX generates stronger free cash flow (122M), providing more financial flexibility.

Bottom Line

EFX scores higher overall (66/100 vs 52/100) and 14.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Equifax Inc

INDUSTRIALS · CONSULTING SERVICES · USA

Equifax Inc. is an American multinational consumer credit reporting agency and is one of the three largest consumer credit reporting agencies, along with Experian and TransUnion. In addition to credit and demographic data and services to business, Equifax sells credit monitoring and fraud prevention services directly to consumers.

SBC Medical Group Holdings Incorporated

INDUSTRIALS · CONSULTING SERVICES · USA

SBC Medical Group Holdings, incorporated in Delaware in 2023 and headquartered in Tokyo, Japan, provides management services to cosmetic treatment centers primarily in Japan, with additional locations in Vietnam and California.

Visit Website →

Want to dig deeper into these stocks?